ReviewTherapeutic advances in medical oncology2025
Prognostic utility of inflammatory indices and circulating nucleic acids for neoadjuvant chemotherapy outcomes in breast cancer: a systematic review.
Review in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemotherapy (NAC) plays a central role in the management of early breast cancer (BC), offering prognostic information and improving surgical outcomes. Blood-based biomarkers, including inflammatory markers-such as neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR)-and circulating nucleic acids-such as circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and cfDNA integrity index (cfDI)-have been investigated for their potential to predict treatment response. Objectives: To systematically evaluate the prognostic value of inflammatory indices and circulating nucleic acids measured during NAC for predicting pathological complete response (pCR) in early BC. Design: Systematic review with qualitative synthesis. Data sources and methods: Twenty-four studies were included, examining changes in NLR, PLR, ctDNA, cfDNA, and cfDI during NAC. Study quality was assessed using the Newcastle-Ottawa Scale, and the strength of evidence was evaluated with a qualitative GRADE approach. Due to heterogeneity in biomarker definitions, sampling timepoints, and statistical methods, data were synthesized narratively. Results: A reduction in PLR from baseline to mid-NAC (ΔPLR <0) was consistently associated with higher pCR rates. ctDNA clearance, particularly at mid- and post-NAC, was frequently linked to increased pCR and better overall survival. In contrast, findings on NLR dynamics were inconsistent. Evidence for cfDNA and cfDI was limited and mixed, with some studies suggesting lower cfDNA and higher cfDI may be associated with improved outcomes. Variability in biomarker thresholds and timepoints was a common limitation. Conclusion: Mid-NAC PLR decrease and ctDNA clearance show moderate evidence as predictors of pCR and may help guide treatment decisions. The prognostic value of NLR, cfDNA, and cfDI remains uncertain and requires further prospective, standardized investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.